Core Viewpoint - The company has released its 2025 semi-annual report, which includes financial performance, management of raised funds, and plans for future development [1][10][32]. Group 1: Company Overview - The company is Qingdao Impulse Health Technology Co., Ltd., with stock code 002899 [1]. - The company has not changed its controlling shareholder or actual controller during the reporting period [5][6]. Group 2: Financial Data and Performance - The company reported a total fundraising amount of RMB 481.5 million from its initial public offering, with a net amount of RMB 433.2 million after deducting issuance costs [33]. - In 2022, the company raised RMB 386.1 million through a private placement, with a net amount of RMB 379.7 million after costs [34]. Group 3: Fund Management and Usage - The company has established specific accounts for managing raised funds, ensuring compliance with regulations [36]. - As of June 30, 2025, the company has detailed the usage of raised funds in its reports, confirming that all funds have been used according to the planned projects [46]. Group 4: Board and Supervisory Meetings - The fourth board meeting of 2025 was held on August 29, where the semi-annual report and the special report on the management of raised funds were approved unanimously [20][22]. - The supervisory board also confirmed that the report accurately reflects the company's situation without any misleading statements [11]. Group 5: Upcoming Shareholder Meeting - The company will hold its first extraordinary general meeting of 2025 on September 16, 2025, to discuss various proposals, including changes to the company’s registered address and amendments to the articles of association [52][75].

Fundraising Overview - The company raised a total of RMB 302,495.13 million by issuing 19,851,367 shares at a price of RMB 152.38 per share, with a net amount of RMB 273,079.07 million after deducting issuance costs [1][19] - As of June 30, 2025, the balance in the fundraising special account was RMB 16,199.4 million, with RMB 94,300 million used for cash management and RMB 57,497.87 million invested in projects [2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations, ensuring dedicated storage and management of the raised funds [3] - A tripartite supervision agreement has been signed with the sponsor and banks holding the fundraising account to ensure proper oversight [4] Fund Usage - The company has not used idle funds for temporary working capital as of June 30, 2025 [6] - The company has approved the use of up to RMB 180,000 million of idle funds for cash management, investing in low-risk financial products with a maturity of no more than 12 months [7][8] - As of June 30, 2025, the balance of idle funds under cash management was RMB 94,300 million [9] Project Investment - The company has not made any pre-investments or replacements for fundraising projects during the reporting period [5] - The company has replaced RMB 10,979.33 million of its own funds with raised funds for project payments [12] - All fundraising projects, including the X-ray source industrialization project and R&D center construction project, have been completed with no surplus funds [12] Changes in Fundraising Projects - There have been no changes or transfers of fundraising projects as of June 30, 2025 [13][14] Compliance and Disclosure - The company has complied with disclosure requirements regarding the management and usage of raised funds, with no violations reported [15]

证券代码：688173 证券简称：希荻微 公告编号：2025-068 希荻微电子集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》 （以下简称" 《募集资金监管规则》"）以 及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下 简称"《规范运作》"）等相关规定，希荻微电子集团股份有限公司（以下简称"公 司"）就 2025 年半年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经中国证券监督管理委员会《关于同意广东希荻微电子股份有限公司首次公 开发行股票注册的批复》 （证监许可〔2021〕3934 号）同意注册，并经上海证券 交易所同意，公司向社会公众公开发行人民币普通股 4,001 万股，每股面值人民 币 1.00 元，每股发行价为人民币 33.57 元，募集资金总额为人民币 134,313.57 万元，扣除发行费用后的募集资金净额为人民币 122,140.85 万元。上述募集资金 已全部到位，业经普华 ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the utilization of raised funds by Hainan Huluwa Pharmaceutical Group Co., Ltd. for the first half of 2025, highlighting the total amount raised, expenses incurred, and the allocation of funds to various projects. Fundraising Basic Situation - The company raised a total of RMB 208,119,000.00 by issuing 40,100,000 shares at RMB 5.19 per share, with net proceeds amounting to RMB 173,119,000.00 after deducting underwriting fees of RMB 35,000,000.00 [1][2]. - The funds were deposited into a regulatory account managed by the lead underwriter, CITIC Securities Co., Ltd. [1]. Fundraising Usage and Balance - As of June 30, 2025, the total amount of raised funds was RMB 208,119,000.00, with total expenses of RMB 57,079,347.77, resulting in a net amount of RMB 151,039,652.23 [2]. - The remaining balance of the raised funds at the end of the period was RMB 11,878,482.50 after accounting for various expenditures and interest income [2][4]. Fund Management and Storage - The company established a dedicated account for the management of raised funds, adhering to relevant regulations and guidelines to ensure proper usage and protection of investor interests [2][3]. - A tripartite supervision agreement was signed with the banks and the underwriter to clarify the rights and obligations of all parties involved [2][3]. Project Adjustments and Fund Allocation - The company adjusted the implementation of the "Marketing System Construction and Brand Promotion Project" to be managed by its wholly-owned subsidiary, Hainan Huluwa Pharmaceutical Co., Ltd. [3]. - The company decided to reallocate funds from the "Pediatric Drug Research Project" to other urgent drug research projects due to delays in the original project [10][11]. Financial Performance and Future Outlook - The company reported that the fundraising projects do not directly generate economic benefits, making it challenging to assess their individual performance [6][11]. - The long-term benefits of the drug research projects are expected to enhance the company's core competitiveness and market presence [6][7]. Compliance and Disclosure - The company confirmed compliance with all relevant laws and regulations regarding the use of raised funds and timely disclosure of information [12][13]. - There were no violations in the use of raised funds, and all disclosed information accurately reflects the company's financial activities [12].

Core Viewpoint - The company has not faced any penalties from regulatory authorities or stock exchanges in the last five years, indicating a strong compliance record and governance structure [1][4]. Summary by Sections Recent Penalties - The company has not been penalized by securities regulatory authorities or stock exchanges in the last five years [1]. Regulatory Measures and Rectification - **Fundraising Related Oral Warning**: The company received an oral warning regarding the distribution of dividends amounting to 2.7675 million yuan to shareholders of restricted shares without timely reporting. The funds were returned to the designated account by June 30, 2020, but the company failed to disclose this issue until August 19, 2020, violating multiple regulations [1][2]. - **Rectification Actions**: The company has organized training on relevant laws and regulations regarding the management and use of raised funds, aiming to ensure compliance and protect shareholder rights [2]. - **Related Party Transactions Oral Warning**: An oral warning was issued for failing to disclose a related party transaction amounting to 13.6589 million yuan, which constituted 1.3% of the company's audited net assets as of the end of 2020. The company did not follow the necessary approval and disclosure procedures [2][3]. - **Rectification Actions**: The company has taken steps to enhance understanding of laws and internal regulations regarding related party transactions and has improved the information disclosure process to ensure compliance [3]. Other Compliance Status - The current directors, supervisors, and senior management have not faced administrative penalties from the China Securities Regulatory Commission in the last three years, nor have they received public reprimands from stock exchanges in the last year. This indicates that the company meets the criteria for issuing shares to specific objects under simplified procedures [4].

Core Viewpoint - The company has approved the use of its own funds and bank acceptance bills to pay for part of the fundraising investment projects, with plans to replace these payments with raised funds later, ensuring efficient fund utilization and compliance with regulations [1][7][8]. Fundraising Overview - The company successfully raised a total of RMB 944.236 million by issuing 40.01 million shares at RMB 23.60 each, with a net amount of RMB 855.914 million after deducting issuance costs [1]. - The total amount of over-raised funds is RMB 65.914 million, and all raised funds have been received and verified by an accounting firm [1]. Fund Utilization Plan - The net proceeds from the fundraising will be allocated to projects related to the company's main business, including a low-melting-point polyester fiber project and a regenerated short fiber research center, with a total investment of RMB 1145.315 million [2][3]. Reasons for Using Own Funds - The company needs to use its own funds and bank acceptance bills for initial payments due to regulatory requirements regarding salary payments and tax obligations, which cannot be processed through the fundraising account [5][6]. - Using own funds for small expenses like travel costs is more operationally convenient and efficient, enhancing overall management [5][6]. Operational Process - The company will establish a detailed ledger and summary table for payments made with its own funds and will regularly apply for replacements from the fundraising account [6]. - The financial department will oversee the payment process, ensuring compliance with internal approval procedures [6]. Impact on Daily Operations - The use of own funds for project payments will not affect the company's normal cash flow or the implementation of fundraising projects, aligning with the interests of all shareholders [5][8]. Review Procedures - The board and supervisory committee have approved the proposal, confirming that the process adheres to necessary legal and regulatory requirements [7][8].

Core Viewpoint - The document outlines the fundraising management system of Zhejiang Century Huatong Group Co., Ltd., emphasizing the proper storage, management, and utilization of raised funds to enhance their effectiveness and ensure compliance with relevant laws and regulations [1]. Group 1: General Provisions - The fundraising refers to funds raised through the issuance of stocks or other equity-like securities for specific purposes, excluding funds raised for equity incentive plans [1]. - The company must ensure that subsidiaries or controlled entities comply with the fundraising management system [1]. Group 2: Fund Storage and Management - The company is required to store raised funds in a special account approved by the board of directors and must sign a tripartite supervision agreement with the sponsor and the commercial bank within one month of the funds being in place [2]. - The tripartite agreement must include details such as the special account number, project details, and withdrawal notifications for significant amounts [2][3]. Group 3: Fund Utilization - The company must use raised funds prudently, ensuring alignment with the commitments made in the issuance application documents and must not change the investment direction without proper procedures [4]. - Funds must be used specifically for the main business and should not be allocated for high-risk investments or financial assistance to others [4][5]. Group 4: Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed promptly, especially if it involves new projects or permanent funding [11][12]. - The company must conduct feasibility analyses for new investment projects to ensure they have good market prospects and profitability [23]. Group 5: Fund Management and Supervision - The accounting department must maintain detailed records of the usage of raised funds, and internal audits should be conducted quarterly [28]. - The board of directors must regularly review the actual storage, management, and usage of raised funds and report any discrepancies [29][30].

证券代码：688173 证券简称：希荻微 公告编号：2025-067 希荻微电子集团股份有限公司 第二届监事会第二十一次会议决议公告 希荻微电子集团股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 8 月 29 日在公司会议室召开，本次会议采用现场和通讯方式召 开，会议应到监事 3 名，实到监事 3 名。本次会议由公司监事会主席李家毅先生 主持。会议的召集和召开程序符合《中华人民共和国公司法》和《希荻微电子集 团股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，表决形成的决议 合法、有效。 二、监事会会议审议情况 本次会议由监事会主席李家毅先生主持，以记名投票表决方式审议通过以 下议案： （一）审议通过《关于 <公司 ensp="ensp" 年半年度报告="年半年度报告"> 及其摘要的议案》 经核查，公司监事会认为：公司严格按照上市公司财务制度规范运作，公司 成果。公司 2025 年半年度报告的编制和审议程序符合法律、法规、《公司章程》 和公司内部管理制度的各项规定。公司全体监事保证公司 2025 年半年度报告所 披露的信息真实、准确、完整，承诺本报告所载内容不存在任何虚 ...

Core Viewpoint - The company held its 19th meeting of the 12th Supervisory Board on August 28, 2025, where several key resolutions were passed regarding the company's financial reports, fundraising management, stock option plan, and structural changes to the supervisory framework [1][2][3][4]. Group 1: Financial Reports - The Supervisory Board approved the company's 2025 semi-annual report and summary, confirming that the report's preparation and review processes complied with legal and regulatory requirements, accurately reflecting the company's operational and financial status [1]. - The board also approved a special report on the storage and actual use of raised funds, affirming that the company disclosed this information timely and accurately, with no violations in fund management [2]. Group 2: Stock Option Plan - The board approved the cancellation of unexercised stock options from the 2019 stock option incentive plan, stating that this action complies with relevant laws and regulations, and does not harm the interests of the company or its shareholders [2]. Group 3: Structural Changes - The board approved the proposal to abolish the Supervisory Board and amend the company's articles of association, transferring the supervisory functions to the Audit Committee of the Board, in line with updated legal and regulatory requirements [3][4]. - The board also approved the proposal to abolish the "Supervisory Meeting Rules," which will be submitted for shareholder approval [4].

Fundraising Overview - The company raised a total of RMB 726.5 million by issuing 10 million shares at RMB 72.65 each, with a net amount of RMB 652.76 million after deducting issuance costs of RMB 73.74 million [1][2] - As of the report date, all raised funds have been received and verified by an accounting firm [2] Fund Utilization and Balance - Cumulative usage of the raised funds reached RMB 283.99 million, with RMB 31.16 million used in the first half of 2025 [2][6] - The company has RMB 380 million temporarily idle for cash management, with a remaining balance of RMB 18.24 million in the fundraising account [2][6] Fund Management System - The company established a fundraising management system to ensure the safety and efficiency of fund usage, complying with relevant laws and regulations [2][3] - A tripartite supervision agreement was signed with a bank and a sponsor to ensure strict approval for fund usage [3] Cash Management of Idle Funds - The company approved the use of up to RMB 430 million of temporarily idle funds for cash management, investing in safe and liquid financial products [4][5] - The report details various structured deposits and their expected returns, indicating a focus on capital preservation [5][6] Compliance and Reporting - The company has adhered to disclosure requirements, ensuring timely and accurate reporting of fundraising and usage status, with no violations noted [6][7]